Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jun 4;16(6):e0252654. doi: 10.1371/journal.pone.0252654

Characteristics and outcomes of pregnant women with placenta accreta spectrum in Italy: A prospective population-based cohort study

Sara Ornaghi 1,*, Alice Maraschini 2, Serena Donati 2; on behalf of The Regional Obstetric Surveillance System Working Group
Editor: Clive J Petry3
PMCID: PMC8177430  PMID: 34086797

Abstract

Introduction

Placenta accreta spectrum (PAS) is a rare but potentially life-threatening event due to massive hemorrhage. Placenta previa and previous cesarean section are major risk factors for PAS. Italy holds one of the highest rates of primary and repeated cesarean section in Europe; nonetheless, there is a paucity of high-quality Italian data on PAS. The aim of this paper was to estimate the prevalence of PAS in Italy and to evaluate its associated factors, ante- and intra-partum management, and perinatal outcomes. Also, since severe morbidity and mortality in Italy show a North-South gradient, we assessed and compared perinatal outcomes of women with PAS according to the geographical area of delivery.

Material and methods

This was a prospective population-based study using the Italian Obstetric Surveillance System (ItOSS) and including all women aged 15–50 years with a diagnosis of PAS between September 2014 and August 2016. Six Italian regions were involved in the study project, covering 49% of the national births. Cases were prospectively reported by a trained clinician for each participating maternity unit by electronic data collection forms. The background population comprised all women who delivered in the participating regions during the study period.

Results

A cohort of 384 women with PAS was identified from a source population of 458 995 maternities for a prevalence of 0.84/1000 (95% CI, 0.75–0.92). Antenatal suspicion was present in 50% of patients, who showed reduced rates of blood transfusion compared to unsuspected patients (65.6% versus 79.7%, P = 0.003). Analyses by geographical area showed higher rates of both concomitant placenta previa and prior CS (62.1% vs 28.7%, P<0.0001) and antenatal suspicion (61.7% vs 28.7%, P<0.0001) in women in Southern compared to Northern Italy. Also, these women had lower rates of hemorrhage ≥2000 mL (29.6% vs 51.2%, P<0.0001), blood transfusion (64.5% vs 87.5%, P = 0.001), and severe maternal morbidity (5.0% vs 11.1%, P = 0.036). Delivery in a referral center for PAS occurred in 71.9% of these patients.

Conclusions

Antenatal suspicion of PAS is associated with improved maternal outcomes, also among high-risk women with both placenta previa and prior CS, likely because of their referral to specialized centers for PAS management.

Introduction

Placenta accreta spectrum (PAS) is an obstetric condition caused by excessive trophoblast invasion into the myometrium of the uterine wall [1]. Defective decidualization in an area of scarring, mostly due to previous uterine surgery, is supposed to be the main underlying mechanism of PAS [2].

Prevalence of PAS ranges from 0.01 to 1.1% [3, 4], and it has progressively increased due to the raising rate of cesarean sections (CS), and alongside that of placenta previa [47]. Placenta previa after prior CS is the most important risk factor for PAS, with 11%, 40%, and 61% rate of PAS in case of placenta previa associated to one, two, or three previous CS, respectively [811]. Maternal age ≥35 years, high parity, prior uterine surgeries other than CS, history of infertility, and infertility-related procedures are additional risk factors [1216].

Although rare, PAS represents a potentially life-threatening event, especially if not suspected before delivery [17, 18]. It may result in massive hemorrhage ultimately requiring emergency hysterectomy to prevent maternal death [1921]. Thus, PAS can be considered a “near-miss” event [17, 22]. “Near-miss” events are proxies of maternal health care quality, and their monitoring and in-depth investigation provide an essential feedback to improve obstetric care [23].

Considering that hemorrhage is the leading cause of maternal mortality and morbidity in Italy [24, 25], where there is a paucity of high-quality studies on PAS notwithstanding high rates of CS [2631], the Italian Obstetric Surveillance System (ItOSS) carried out a prospective, population-based study on hemorrhagic “near-miss” events, including PAS.

The aim of this paper is to estimate the incidence of PAS and to analyze its associated factors, management, and perinatal complications. In addition, since Italy has regional health care imbalances with the South displaying higher rates of morbidity and mortality [20, 25], outcomes were compared according to the geographical area of delivery.

Material and methods

This is a prospective, population-based study including all women aged 15–50 years and delivering at ≥22 weeks of gestation with a diagnosis of PAS from September 2014 to August 2016 in six Italian regions covering 49% of the national births. These regions were selected by annual number of births (≥25 000) and to ensure the representativeness of the Northern (Piedmont, Emilia Romagna, and Tuscany) and Southern (Lazio, Campania and Sicily) areas.

The present study is part of a wider research project on severe maternal morbidity due to obstetric hemorrhage coordinated by the ItOSS, as previously reported [20]. Briefly, the ItOSS project prospectively collected data on women delivering at ≥22 weeks of gestation with any of the following complications: (1) severe postpartum hemorrhage, defined as “hemorrhage within 7 days from delivery requiring ≥4 units of whole blood or packed red blood cells”; (2) “hemorrhage due to complete or incomplete uterine rupture”; (3) “peripartum hysterectomy within 7 days from delivery”; and (4) PAS, clinically defined as “difficult or incomplete manual removal of the placenta following vaginal delivery and the need of blood transfusion within 48 hours” or “difficult removal of the placenta during cesarean delivery and clinical evidence of an abnormally invasive placenta”.

The present study includes all cases of PAS as defined in (4), independent of the associated outcomes, such as severe postpartum hemorrhage (1), uterine rupture (2), and peripartum hysterectomy within 7 days from delivery (3), leading to inclusion in the wider ItOSS research project.

All maternity units in the selected regions were invited to participate in the study and to appoint a clinician as reference person for reporting incident cases. Unified electronic data collection forms, prepared by a team of national experts by adapting the forms of the Nordic Obstetric Surveillance Study [32], were used for data collection. Each reference person was trained to use the web system for data collection before study’s commencement, and received a monthly reminder by email to promote complete reporting. A multidisciplinary audit involving all healthcare professionals that assisted the women with PAS diagnosis was recommended in each participating maternity unit.

Statistical analyses

The prevalence rate was calculated as the number of PAS per 1000 maternities with a 95% CI, assuming the Poisson approximation to the binomial distribution. When available, the background population was retrieved from the National Hospital Discharge database by selecting all women aged 15–50 who delivered during the same study period in the participating maternity units of the selected regions. When not available, the background population was estimated in aggregate form from the National Birth Register, year 2015 [33].

Potential factors associated to PAS were identified by calculating unadjusted relative risks (RR) and 95% CI. Dichotomous data were compared using Pearson Chi-square test or Fisher exact test for categorical variables and Mann-Whitney test for continuous variables.

Analyses were performed using SPSS 26.0 (IBM Corp., NY, USA) and Stata/MP 14.2 (Stata Corp., TX, USA).

Ethical approval

The study was approved by the Ethics Committee of the Italian National Institute of Health (Prot. PRE-839/13). Data were fully anonymized before being accessed and analyzed. Thus, need for informed consent was waived by the local Ethics Committee.

Results

Seven of the 212 maternity units in the six selected regions did not provide the requested data, for a 96.7% participation rate.

PAS rate and associated factors

During the study period, there were 372 cases of PAS notified. Assessment of data completeness led to recovery of twelve additional cases, for a total of 384 cases out of 458 995 maternities with an estimated prevalence of 0.84 per 1000 (95% CI, 0.75–0.92).

Along with the regional and overall estimates of the PAS rate, Fig 1 shows the contribution to the PAS rate given by women with both placenta previa or low-lying and previous CS. The solid line describes the percentage of women with previous CS in the background population.

Fig 1. Regional and overall PAS rate and percentage of previous cesarean section in the background population.

Fig 1

Bar graphs show regional and overall prevalence distribution of PAS with the 95% CI (white bars and black lines). Grey bars display the contribution to the regional and overall PAS rate given by women with both placenta previa or low-lying and previous cesarean section. Both white and grey bars are plotted on the left Y axis. Solid line with dots shows regional and overall rate of previous cesarean section in the background population (plotted on the right Y axis).

Women with PAS had a median age of 35 years (IQR, 31.4–39.0 years) at delivery; six women were older than 45 and one younger than 20 years (Table 1). PAS patients were mostly Italian with a low education level and more likely multiparas. Overall, 54% had a previous CS, with 18.5% and 6.5% having two or ≥ three previous CS, respectively. Placenta previa or low-lying was diagnosed in 60% of women. In 44.6% of cases there was both a placenta previa or low-lying and a prior CS.

Table 1. Distribution of PAS by maternal sociodemographic characteristics, obstetric history, and current pregnancy course and outcomes.

Variables PAS N = 384 Background population a N = 458 995 Rate ‰ 0.84 RR (95% CI)
N % N %
Maternal characteristics Maternal age • <35 years 184 47.9 309 940 67.5 0.59 ref.
• ≥35 years 200 52.1 149 055 32.5 1.34 2.26 (1.85–2.76)
Citizenship (5 missing) • Italian 308 80.2 373 258 81.3 0.83 ref.
• Not Italian 71 18.5 85 737 18.7 0.83 1.00 (0.78–1.30)
Education level b (44 missing) • High 75 19.5 126 683 c 27.6 0.59 ref.
• Low 265 69.0 332 313 c 72.4 0.80 1.35 (1.04–1.74)
Smoking during pregnancy (119 missing) • No 227 59.1 NA NA
• Yes 38 9.9
Pregestational BMI (51 missing) • <30 Kg/m2 301 78.4 NA NA
• ≥30 Kg/m2 32 8.3
Obstetric history Parity (5 missing) • Nulliparas 122 31.8 251 988 54.9 0.48 ref.
Multiparas 257 66.9 207 007 45.1 1.24 2.56 (2.07–3.18)
 • ≥3 37 9.6 6 960 c 1.52 5.32 4.81 (3.40–6.81)
Previous CS and/or uterine surgery d (5 missing) • Neither one 109 28.4 333 919 72.8 0.33 ref.
• Uterine surgery, no CS 63 16.4 47 827 10.4 1.32 4.04 (2.96–5.50)
• CS, no uterine surgery 133 34.6 61 414 13.4 2.17 6.63 (5.15–8.55)
 • 1 63 16.4 50 627 11.0 1.24 3.81 (2.80–5.20)
 • ≥2 62 16.1 10 786 2.4 5.75 17.61 (12.90–24.04)
Previous PPH • No 369 96.1 NA NA
• Yes 15 3.9
Current pregnancy ART (9 missing) • No 347 90.4 450 825 c 98.2 0.77 ref.
• Yes 28 7.3 8 170 c 1.8 3.43 4.45 (3.03–6.54)
Multiple gestation (18 missing) • No 354 92.2 451 766 98.4 0.78 ref.
• Yes 12 3.1 7229 1.6 1.66 2.12 (1.19–3.76)
Placenta previa or low-lying • No 156 40.6 456 067 99.4 0.34 ref.
• Yes 228 59.4 2 928 0.6 77.9 227.65 (186.31–278.16)
Delivery Geographical location of delivery • Northern Italy 136 35.4 190 018 41.4 0.72 ref.
• Southern Italy 248 64.6 268 977 58.6 0.92 1.29 (1.05–1.59)
Mode of delivery (7 missing) • Vaginal delivery 91 23.7 282 232 c 61.5 0.32 ref.
 • spontaneous 74 19.3 266 893 c 58.1 0.28 0.86 (0.63–1.17)
 • operative 17 4.4 15 339 c 3.34 1.11 3.44 (2.05–5.77)
• Cesarean section 286 74.5 176 763 c 38.5 1.62 5.02 (3.96–6.35)
 • emergent/urgent 76 19.8 63 548 c 13.8 1.20 3.71 (2.74–5.03)
 • elective 210 54.7 113 215 c 24.7 1.85 5.75 (4.50–7.36)
Gestational age at delivery (12 missing) • ≥37 wks 175 45.6 427 490 c 93.1 0.41 ref.
• <37 wks 197 51.3 31 505 c 6.9 6.25 15.27 (12.47–18.72)
 • 32–36 wks 172 44.8 27 062 c 5.9 6.36 15.53 (12.58–19.16)
 • 22–31 wks 25 6.5 4 443 c 1.0 5.63 13.57 (9.05–20.88)

BMI, Body Mass Index; CS, cesarean section; PPH, postpartum hemorrhage; ART, Assisted Reproductive Technology.

a Source: National Discharge Register;

b Education level: high ≥ university degree, low < university degree;

c Source: National Birth Register year 2015 for the six Italian regions involved in the study;

d Uterine surgery included dilation & curettage, surgical termination of pregnancy, endometrial ablation, operative hysteroscopy, myomectomy, and metroplasty.

Among the 122 (31.8%) nulliparous patients, 42.6% were ≥35 years old, 46.7% had either a history of uterine surgery or an ART-conceived pregnancy, and 28.7% had a placenta previa or low-lying. In 35/122 women, none of these factors was identified.

Delivery occurred in facilities in Southern Italy in 65% of the cases. These women showed higher rates of Italian citizenship (89.3% vs 66.9%, P<0.0001), low education level (81.0% vs 72.6%, P = 0.048), multiparity (75.3% vs 54.4%, P<0.0001), previous CS (65.8% vs 34.6%, P<0.0001), placenta previa or low-lying (72.6% vs 35.3%, P<0.0001), and a combination of the last two conditions (62.1% vs 28.7%, P<0.0001). In turn, PAS pregnancies in Northern Italy were more commonly conceived by ART (11.9% vs 5.0%, P = 0.023).

There were 74.5% deliveries by CS, with elective surgery being the most common (73.4%). Median gestational age at delivery was 36 weeks (IQR, 35–38 weeks). Preterm delivery <37 weeks’ gestation occurred in 51.3% of cases, and was more frequent among women with placenta previa or low-lying compared to women without (66.0% vs 16.3%, P<0.0001).

The analysis of maternal characteristics showed a substantially higher risk of PAS in women with placenta previa or low-lying and with previous CS or other uterine surgery, with the greatest risk increase for ≥2 previous CS (RR 17.6; 95% CI, 12.9–24.0). A modest risk increase was also observed for maternal age ≥35 years, multiparity, low education level, and delivery in Southern Italy (Table 1). Also, ART and multiple gestation significantly increased PAS risk. In addition, women with PAS showed a 5- and 15-fold increase in the odds of delivering by CS and <37 weeks’ gestation, respectively.

Pregnancy, delivery, and perinatal outcomes of PAS

PAS was antenatally suspected in 50% of the cases, more likely in multiparas with prior uterine surgery, placenta previa or low-lying, or a combination of both (Table 2). These conditions were more frequent among women in Southern Italy, and, accordingly, a higher rate of antenatal suspicion was identified (61.7% vs 28.7%, P<0.0001).

Table 2. Maternal characteristics, PAS management, and perinatal outcomes stratified according to antenatal suspicion of PAS.

Variables Antenatal suspicion of PAS P-value
Total Yes No
N = 384 N = 192 (50%) N = 192 (50%)
N % N % N %
Obstetric data Multiparity (5 missing) 257 66.9 166 86.5 91 47.4 <0.0001
Previous CS and/or uterine surgery (5 missing) 270 70.3 165 85.9 105 54.7 <0.0001
Placenta previa or low-lying 228 59.4 186 96.9 42 21.9 <0.0001
Previous CS and placenta previa or low-lying (5 missing) 169 44.0 144 75.0 25 13.0 <0.0001
Delivery location, mode, and timing Hospital with ≥1 000 annual births 260 67.9 127 66.1 133 69.6 0.512
Hospital with <500 annual births 21 5.5 4 2.1 17 8.9 0.003
High-level hospital setting (20 missing)a 190 49.5 128 66.7 62 32.3 <0.0001
Mode of delivery (7 missing) <0.0001
 • Vaginal spontaneous 74 19.3 0 0 74 40.0
 • Vaginal operative 17 4.4 0 0 17 9.2
 • Urgent/emergent CS 76 19.8 36 18.8 40 21.6
 • Elective CS 210 54.7 156 81.3 54 29.2
Preterm delivery <37 weeks (12 missing) 197 51.3 141 74.6 56 30.6 <0.0001
 • 32–36 weeks 172 44.8 127 67.2 45 24.6
 • 22–31 weeks 25 6.5 14 7.4 11 6.0
Entity and management of PAS-related hemorrhage Blood loss ≥2000 mL (61 missing) 123 32.0 62 32.3 61 31.8 0.513
First- and second-line uterotonic drugs
Oxytocin 188 49.0 87 45.3 101 52.6 0.184
Prostaglandins 68 17.7 23 12 45 23.4 0.005
Methylergometrine 8 2.1 0 0 8 4.2 0.007
Mechanical and surgical procedures
Manual removal of the placenta and/or uterine curettage 48 12.5 4 2.1 32 16.7 <0.0001
Uterine tamponade 121 31.5 54 28.1 67 34.9 0.187
Uterine artery embolization 100 26.0 87 45.3 13 6.8 <0.0001
Intravascular tamponade 4 1.0 4 2.1 0 0 0.123
Uterine hemostatic sutures 44 11.5 28 14.6 16 8.3 0.077
Vascular hemostatic sutures 6 1.6 4 2.1 2 1.0 0.685
Hysterectomy 191 49.7 127 66.1 64 33.3 <0.0001
Blood products
RBC unit transfusion 279 72.7 126 65.6 153 79.7 0.003
 • ≥4 RBC units 102 26.6 59 30.7 43 22.4 0.083
Plasma transfusions 101 26.3 44 22.9 57 29.7 0.164
Platelets transfusion 14 3.6 6 3.1 8 4.2 0.787
Fibrinogen 23 6.0 11 5.7 12 6.3 1.000
Perinatal outcomes ICU admission (8 missing) 92 24.5 43 22.4 49 26.6 0.401
Severe maternal morbidity (8 missing)b 27 7.2 11 5.7 16 8.7 0.319
Maternal mortality (10 missing) 1 0.3 0 0 1 0.5 1.000
Perinatal mortality (13 missing) c 8 2.1 3 1.6 5 2.6 0.592

CS, cesarean section; RBC, red blood cell; ICU, intensive care unit.

a High-level hospital setting was defined as a hospital with availability of ICU and interventional radiology, and possibility of blood transfusion within 15 minutes;

b Severe maternal morbidity included vegetative state (n = 1), cardiac arrest (n = 2), respiratory distress (n = 3), acute pulmonary edema (n = 2), disseminated intravascular coagulopathy (n = 6), acute renal failure (n = 1), deep vein thrombophlebitis or pulmonary embolism (n = 1), sepsis or septic shock (n = 1), hemorrhagic shock (n = 7). Damage to adjacent organs during surgery and post-operative complications are described separately (details in the text);

c Lazio region excluded.

Most of the suspected women delivered in a high-level hospital setting and by a scheduled CS. None of the 35 women without risk factors for PAS was suspected prenatally, and 26 (74.3%) of them delivered vaginally.

Overall, 32% of patients experienced severe postpartum hemorrhage (PPH) ≥2000 mL. Although suspicion did not impact blood loss (median, IQR: 1500 mL, 1000–2000 mL vs 1500 mL, 1000–2100 mL; P = 0.226), it influenced PPH management, with higher rates of surgical treatment, including hysterectomy, in suspected cases (Table 2). Overall, 49.7% of women underwent hysterectomy, mostly as peripartum procedure (95.3%). Damage of adjacent organs during hysterectomy occurred in 23/191 women, more frequently when PAS was suspected (16.9% vs 5.2%, P = 0.032). Similarly, patients with antenatal suspicion were more likely to experience post-surgery complications (n = 24, 18.9% vs n = 5, 7.9%; P = 0.035), including urological (n = 27) and vascular (n = 2). Of note, all 23 women with complications during surgery and 28/29 women with post-hysterectomy complications had a previous CS in their obstetric history. Also, in 21/23 and 26/29 patients there was a placenta previa or low-lying.

Four women were managed conservatively: three had a partial placenta accreta diagnosed after delivery and only the abnormally adherent cotyledon was left in situ whereas the remaining one had an antenatal diagnosis of complete placenta previa with signs of percretion and no attempt of placenta removal was performed at the time of CS. Follow up of these patients was not available at the time of data collection.

Almost 73% of women were transfused with RBC units, with higher rates among unsuspected women (Table 2).

At least one severe maternal morbidity condition was identified in 27 (7.0%) women, with hemorrhagic shock (n = 7) and disseminated intravascular coagulopathy (DIC, n = 6) being the most frequent. Twelve (3.1%) patients were assisted with mechanical ventilation, and 24% required admission to the ICU. There were no differences in rate of severe maternal morbidity or ICU admission between women with and without suspected PAS (Table 2). Overall, there were 51 (13.3%) patients experiencing organ damage during surgery, post-surgical complications, or a severe maternal morbidity condition.

There was one maternal death in the study cohort, for a fatality rate of 2.6‰; it occurred in a primiparous young woman with no risk factors for PAS and no antenatal diagnosis, who delivered vaginally and experienced uterine inversion in the attempt of removing a partially attached placenta with subsequent severe PPH, DIC, cardiac arrest, and death.

Among 398 infants who were given birth to (372 singletons, ten twins, and two triplets), eight perinatal deaths were identified, for a perinatal mortality rate of 20.1‰: seven (87.5%) cases happened postnatally and in 85.7% of them delivery was before 26 weeks’ gestation.

Assessment of PAS management and perinatal outcomes according to geographical area showed that women in Southern Italy were less likely to bleed ≥2000 mL (29.6% vs 51.2%, P<0.0001), receive RBC units (64.5% vs 87.5%, P = 0.001), be admitted to the ICU (16.5% vs 38.8%, P<0.0001), and experience severe maternal morbidity (5.0% vs 11.1%, P = 0.036). In turn, hysterectomy was more frequently performed (59.3% vs 32.4%, P<0.0001), although with lower rates of intra- and post-operative complications (9.5% vs 25.6%, P = 0.014 and 11.6% vs 27.9%, P = 0.015). Analysis of delivery location among women with suspected PAS in Southern Italy showed that 71.9% of them gave birth in a referral center.

Histology data

Histology report was available at the time of data retrieval in 179 cases, 77.1% of whom had undergone hysterectomy.

Overall, PAS was confirmed in 130 (72.6%) patients; depth of invasion with rates of placenta previa or low-lying and previous CS are shown in Fig 2. All histological diagnoses were performed on both uterine and placental specimen, except for five (3.8%) cases with placenta accreta which were identified by assessment of just the placenta.

Fig 2. Depth of placental invasion at histology.

Fig 2

Bar graphs show depth of placental invasion as defined by histopathology (white bars) and rates of concomitant placenta previa or low-lying and previous cesarean section (grey bars).

PAS was antenatally suspected in 62.7%, 52.4%, and 79.4% of cases with placenta accreta, increta, and percreta, respectively. Women with antenatal diagnosis did not show higher grade of invasion, such as placenta increta or percreta, compared to unsuspected women (44.7% vs 37.8%, p = 0.463). However, when analysis was performed by geographical area, women in Southern regions were more likely to have more severe forms of PAS than women in the North (46.5% vs 29.0%, P = 0.045).

Rates of PPH ≥2000 mL and of blood transfusion among women with either placenta accreta or placenta increta/percreta and antenatal diagnosis were similar to those of unsuspected women (Table 3).

Table 3. Postpartum bleeding and blood transfusion rates according to antenatal suspicion in patients with histologically diagnosed PAS.

Variables Antenatal suspicion of PAS
Placenta accreta (n = 75) Yes No P-value
N = 47 (62.7%) N = 28 (37.3%)
N (%) N (%)
PPH ≥2000 mL (4 missing) 27 (58.7) 15 (60.0) 1.000
RBC unit transfusion 40 (85.1) 26 (92.9) 0.470
 • ≥4 RBC units 21 (44.7) 13 (46.4) 1.000
Placenta increta or percreta (n = 55) Yes No
N = 38 (69.1%) N = 17 (30.9%)
PPH ≥2000 mL (4 missing) 8 (21.6) 4 (28.6) 0.715
RBC unit transfusion 28 (73.7) 14 (82.4) 0.733
 • ≥4 RBC units 14 (36.8) 5 (29.4) 0.761

PPH, postpartum hemorrhage; RBC, Red Blood Cell.

Discussion

Main findings

This study showed that prevalence of PAS in the participating Italian regions was 0.84‰, with higher rates in Southern Italy.

Results highlighted the pivotal contribution of placenta previa or low-lying, prior CS and/or other uterine surgery, and ART to the occurrence of PAS.

Half of the cases did not have antenatal suspicion, and this occurred also among women with relevant risk factors for PAS such as placenta previa and previous CS. Antenatal suspicion did not associate with improved outcomes in our cohort, except for a lower rate of RBC unit transfusion in suspected women. However, when assessed according to geographical area, adverse outcomes were less likely in patients in Southern regions notwithstanding higher rates of high-risk cases, such as those with both placenta previa and prior CS or placenta increta/percreta.

Strengths and limitations

The strengths of this study include the prospective and population-based design, the high participation rate of the maternity centers, and the opportunity to rely on the ItOSS surveillance system to validate the reported maternal death. Also, although subnational, results are unlikely to be significantly biased due the distribution of the participating regions in all the geographical areas of the country.

There are also limitations.

In order to fully capture all cases of PAS, we used a clinical case definition including also women with vaginal delivery. Although unlikely [34], this may have led to inclusion of cases of common entrapped placenta [35, 36] and thus, to overestimation of PAS prevalence. Of note, the present study was designed and implemented before FIGO guidelines on PAS definition were published [4].

Also, cases without histological confirmation of PAS were considered in the analyses. However, it is known that the absence of histological features indicative of PAS does not necessarily exclude such diagnosis, especially when high clinical suspicion is present [37].

In addition, information regarding blood loss at delivery was lacking in almost 16% of women and this may have led to biased result interpretation. Nevertheless, lack of missingness in first- and second line treatments of PPH has likely limited this possibility.

Another potential limitation is the lack of a PAS code in the ICD-9 Hospital Discharge database to ascertain completeness of notified cases. However, presence of a trained clinician in each hospital, the active monthly checks of ItOSS case reporting, and previous studies using ItOSS that suggested high rates of ascertainment [20], make this possibility unlikely.

Finally, the lack of individual data of deliveries in women without PAS prevented us from adjusting the estimated RRs.

Interpretation

The PAS prevalence reported in this study (0.84‰) is higher than the one reported for the Nordic countries by the NOSS (0.34‰) [36]. This finding might be related to the exclusion of women with vaginal delivery from this work. However, a lower rate of PAS (0.46‰) was still identified when these women were included in a previous analysis [32], thus suggesting a more relevant role of prior CS rate (10% in Nordic countries vs 16.8% in Italy) in causing such a difference [20, 36]. Similarly, the higher rate of prior CS might explain the increased PAS prevalence in Italy compared to France (0.48‰, prior CS rate 11.4%) [38] and to the United Kingdom (0.17‰, prior CS rate 14.9%) [34]. In turn, the use of statistic record-linkage procedures instead of active reporting may account for our lower prevalence estimates compared to a recent Australian-population based study (2.5‰, prior CS rate 14.4%) [16].

High rates of primary CS [39], alongside the policy defined by the axiom "once a cesarean always a cesarean" [40], has led to a considerable increase in women with ≥2 previous CS in the ItOSS cohort (96/384, 25%) compared to the Nordic countries (32/205, 15.6%). It is known that the incidence of placenta previa and of PAS rise with the number of prior CS [810]. According to this and in line with published data [36, 41], we identified a “dose-dependent” relation between prior CS and PAS, with an increase in the RR of PAS from 3.8 for one to 17.6 for ≥ two previous CS.

Antenatal suspicion of PAS has been associated to improved outcomes [18, 4245]. This finding has also been confirmed by the UKOSS study [34]. Although our rate of antenatal suspicion (192/384, 50%) was similar to that reported in this work (66/134, 49.3%), we did not observe any difference in term of blood loss at delivery (Table 2), even when analysis was restricted to only those cases with histological confirmation of placenta increta or percreta (Table 3). Notwithstanding this, we noted a lower rate of RBC unit transfusion among suspected women, thus possibly suggesting a different preparedness to and, thus, management of severe PPH when substantial bleeding is expected at delivery and an adequate planning is put in place [34, 42, 46].

Of note, there were 25 (6.5%) women with both placenta previa or low-lying and prior CS, a combination of risk factors defining a clinical profile at high risk for adverse outcomes [38], who were not antenatally suspected. Knowledge of relevant risk factors for PAS is pivotal to guide a targeted prenatal ultrasound scan and increase the rate of antenatal diagnosis [42, 4755]. However, PAS can also occur in the absence of any known risk factor, as we observed in 35 (9.1%) cases and as reported by the NOSS in 15 (7.3%) cases [36].

Almost half of our patients had a high-risk clinical profile [38]. Although such profile was substantially more common among women in the South compared to the North, we observed improved outcomes with decreased rates of PPH, blood transfusion, ICU admission, and severe maternal morbidity. Also, these women less frequently experienced intra- and post-hysterectomy complications, notwithstanding higher rates of placenta previa and previous CS, conditions known to make surgery more technically challenging [38, 44, 56, 57]. Since referral of expected cases has been suggested as a more important determinant of outcomes than the patient’s clinical risk profile [45, 53, 58], it is plausible that this finding may be related to the higher rate of antenatal diagnosis observed among Southern women (61.7% vs 28.7%) with their subsequent referral to specialized centers, which occurred in 71.9% of the cases.

Altogether our results suggest that outcomes can be optimized even in women with a high-risk clinical profile when high rates of antenatal diagnosis are followed by referral to specialized centers with skilled multidisciplinary teams for PAS management.

Overall, almost 50% of women with PAS underwent hysterectomy in our study cohort, a rate similar to published data [34, 36]. Of note, a previous study from the same working group had reported PAS as the second leading cause (n = 191, 40.2%), after uterine atony (n = 214, 45.1%), of hysterectomy performed within 7 days of delivery for obstetric hemorrhage [20]. In the present work, all cases of PAS identified during the study period (n = 384) were included and assessed in terms of associated factors, management, and outcomes, providing novel Italian population-based data on the topic.

We observed a rate of severe maternal morbidity and peri-operative complications (13.3%) similar to that reported by the UKOSS (18/134, 13.4%) and the NOSS (21/205, 10.2%) [34, 36], with complications derived by severe hemorrhage being the most common.

Rate of maternal death in our study (2.6‰, national rate 0.09‰ [25]), was higher compared to the UKOSS, NOSS, and Australian cohorts, which did not report any fatal case [16, 34, 36], but lower than the French cohort (4.1‰) [38]. Of note, the only death in our cohort occurred in an unsuspected woman without risk factors for PAS.

Also, we calculated a perinatal death rate of 20.8‰ (national rate 4.2‰ [59]) compared to 14.9, 9.8, 13.8, and 12 per 1000 of the UKOSS, NOSS, Australian, and French studies, respectively [16, 34, 36, 38]. Importantly, most of our cases were neonatal deaths occurring after very preterm delivery.

Conclusions

A low CS rate in the population has been already proved as the most effective way to decrease CS-related adverse outcomes, including PAS [36, 60, 61]. Considering that Italy holds one of the highest rate of primary and elective repeat CS among European nations [28, 30], it is urgent to promote educational efforts to support Italian obstetricians in safely reducing primary CS and admitting women with prior CS to a trial of labor [29].

Management in specialized centers should be considered for all high-risk cases as pivotal determinant in improving outcomes [54, 55]. As recommended by the national guideline on PPH prevention and treatment [62], coordinated, multi-faceted efforts should be directed to increase antenatal suspicion of PAS by rising awareness of relevant risk factors with referral of patients at risk for targeted ultrasound assessment by expert sonographers [53, 63].

Acknowledgments

We acknowledge the invaluable work of the Regional Obstetric Surveillance System Working Group, which include: Serena Donati, Alice Maraschini, Paola D’Aloja and Ilaria Lega (National Center for Disease Prevention and Health Promotion, Istituto Superiore di Sanità—Italian National Institute of Health), Vittorio Basevi (Center for Perinatal and Reproductive Health, Emilia-Romagna Region), Giuseppe Cali’ (Department of Obstetrics and Gynecology, Civico Benfratelli Hospital, Palermo, Sicily), Gabriella Dardanoni (Health Department, Sicily Region), Valeria Dubini (Health Department, Tuscany Region), Camilla Lupi (Emilia-Romagna Region), Pasquale Martinelli (Department of Obstetrics and Gynecology, University of Naples Federico II), Luisa Mondo (Piedmont Region), Marcello Pezzella (Health Department, Campania Region), Monia Puglia (Health Department, Tuscany Region), Raffaella Rusciani (Piedmont Region), Daniela Spettoli (Emilia-Romagna Region), Fabio Voller (Health Department, Tuscany Region). The lead author of this group is Serena Donati; e-mail: serena.donati@iss.it.

This study would not have been possible without the enthusiasm and contribution of the ItOSS reporting clinicians who notified the cases and completed the data collection forms. We acknowledge Silvia Andreozzi for her valuable technical support.

Abbreviations

CI

confidence interval

CS

cesarean section

ItOSS

Italian Obstetric Surveillance System

NOSS

Nordic Obstetric Surveillance System

PAS

placenta accreta spectrum

RR

relative risk

UKOSS

United Kingdom Obstetric Surveillance System

Data Availability

Data cannot be shared publicly because of ethical standards and legal requirements. Data are available from the Ethics Committee of the Istituto Superiore di Sanità - Italian National Institute of Health (contact via email: segreteria.comitatoetico@iss.it) for researchers who meet the criteria for access to confidential data.

Funding Statement

S.D. Italian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. American journal of obstetrics and gynecology. 2018;218(1):75–87. Epub 2017/06/11. doi: 10.1016/j.ajog.2017.05.067 . [DOI] [PubMed] [Google Scholar]
  • 2.Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008;29(7):639–45. Epub 2008/06/03. doi: 10.1016/j.placenta.2008.04.008 . [DOI] [PubMed] [Google Scholar]
  • 3.Jauniaux E, Bunce C, Grønbeck L, Langhoff-Roos J. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. American journal of obstetrics and gynecology. 2019;221(3):208–18. Epub 2019/02/05. doi: 10.1016/j.ajog.2019.01.233 . [DOI] [PubMed] [Google Scholar]
  • 4.Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J. FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2018;140(3):265–73. Epub 2018/02/07. doi: 10.1002/ijgo.12407 . [DOI] [PubMed] [Google Scholar]
  • 5.Boerma T, Ronsmans C, Melesse DY, Barros AJD, Barros FC, Juan L, et al. Global epidemiology of use of and disparities in caesarean sections. Lancet (London, England). 2018;392(10155):1341–8. Epub 2018/10/17. doi: 10.1016/S0140-6736(18)31928-7 . [DOI] [PubMed] [Google Scholar]
  • 6.Visser GHA, Ayres-de-Campos D, Barnea ER, de Bernis L, Di Renzo GC, Vidarte MFE, et al. FIGO position paper: how to stop the caesarean section epidemic. Lancet (London, England). 2018;392(10155):1286–7. Epub 2018/10/17. doi: 10.1016/S0140-6736(18)32113-5 . [DOI] [PubMed] [Google Scholar]
  • 7.Silver RM, Branch DW. Placenta Accreta Spectrum. The New England journal of medicine. 2018;378(16):1529–36. Epub 2018/04/19. doi: 10.1056/NEJMcp1709324 . [DOI] [PubMed] [Google Scholar]
  • 8.Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstetrics and gynecology. 2006;107(6):1226–32. Epub 2006/06/02. doi: 10.1097/01.AOG.0000219750.79480.84.79480.84 [DOI] [PubMed] [Google Scholar]
  • 9.Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. American journal of obstetrics and gynecology. 2017;217(1):27–36. Epub 2017/03/08. doi: 10.1016/j.ajog.2017.02.050 . [DOI] [PubMed] [Google Scholar]
  • 10.Keag OE, Norman JE, Stock SJ. Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: Systematic review and meta-analysis. PLoS medicine. 2018;15(1):e1002494. Epub 2018/01/24. doi: 10.1371/journal.pmed.1002494 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Klar M, Michels KB. Cesarean section and placental disorders in subsequent pregnancies—a meta-analysis. Journal of perinatal medicine. 2014;42(5):571–83. Epub 2014/02/26. doi: 10.1515/jpm-2013-0199 . [DOI] [PubMed] [Google Scholar]
  • 12.Baldwin HJ, Patterson JA, Nippita TA, Torvaldsen S, Ibiebele I, Simpson JM, et al. Antecedents of Abnormally Invasive Placenta in Primiparous Women: Risk Associated With Gynecologic Procedures. Obstetrics and gynecology. 2018;131(2):227–33. Epub 2018/01/13. doi: 10.1097/AOG.0000000000002434 . [DOI] [PubMed] [Google Scholar]
  • 13.Esh-Broder E, Ariel I, Abas-Bashir N, Bdolah Y, Celnikier DH. Placenta accreta is associated with IVF pregnancies: a retrospective chart review. BJOG: an international journal of obstetrics and gynaecology. 2011;118(9):1084–9. Epub 2011/05/19. doi: 10.1111/j.1471-0528.2011.02976.x . [DOI] [PubMed] [Google Scholar]
  • 14.Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PloS one. 2012;7(12):e52893. Epub 2013/01/10. doi: 10.1371/journal.pone.0052893 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Salmanian B, Fox KA, Arian SE, Erfani H, Clark SL, Aagaard KM, et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. American journal of obstetrics and gynecology. 2020;223(4):568.e1–.e5. Epub 2020/05/04. doi: 10.1016/j.ajog.2020.04.026 . [DOI] [PubMed] [Google Scholar]
  • 16.Baldwin HJ, Patterson JA, Nippita TA, Torvaldsen S, Ibiebele I, Simpson JM, et al. Maternal and neonatal outcomes following abnormally invasive placenta: a population-based record linkage study. Acta obstetricia et gynecologica Scandinavica. 2017;96(11):1373–81. Epub 2017/08/15. doi: 10.1111/aogs.13201 . [DOI] [PubMed] [Google Scholar]
  • 17.Chantraine F, Langhoff-Roos J. Abnormally invasive placenta—AIP. Awareness and pro-active management is necessary. Acta obstetricia et gynecologica Scandinavica. 2013;92(4):369–71. Epub 2013/03/23. doi: 10.1111/aogs.12130 . [DOI] [PubMed] [Google Scholar]
  • 18.Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta obstetricia et gynecologica Scandinavica. 2011;90(10):1140–6. Epub 2011/04/15. doi: 10.1111/j.1600-0412.2011.01147.x . [DOI] [PubMed] [Google Scholar]
  • 19.Kallianidis AF, Maraschini A, Danis J, Colmorn LB, Deneux-Tharaux C, Donati S, et al. Epidemiological analysis of peripartum hysterectomy across nine European countries. Acta obstetricia et gynecologica Scandinavica. 2020;99(10):1364–73. Epub 2020/05/03. doi: 10.1111/aogs.13892 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Maraschini A, Lega I, D’Aloja P, Buoncristiano M, Dell’Oro S, Donati S. Women undergoing peripartum hysterectomy due to obstetric hemorrhage: A prospective population-based study. Acta obstetricia et gynecologica Scandinavica. 2020;99(2):274–82. Epub 2019/09/15. doi: 10.1111/aogs.13727 . [DOI] [PubMed] [Google Scholar]
  • 21.van den Akker T, Brobbel C, Dekkers OM, Bloemenkamp KWM. Prevalence, Indications, Risk Indicators, and Outcomes of Emergency Peripartum Hysterectomy Worldwide: A Systematic Review and Meta-analysis. Obstetrics and gynecology. 2016;128(6):1281–94. Epub 2016/11/09. doi: 10.1097/AOG.0000000000001736 . [DOI] [PubMed] [Google Scholar]
  • 22.World Health Organization Department of Reproductive Health and Research. Evaluating the Quality of Care for Severe Pregnancy Complications: The WHO Near-Miss Approach for Maternal Health. 2011.
  • 23.Say L, Souza JP, Pattinson RC. Maternal near miss—towards a standard tool for monitoring quality of maternal health care. Best practice & research Clinical obstetrics & gynaecology. 2009;23(3):287–96. Epub 2009/03/24. doi: 10.1016/j.bpobgyn.2009.01.007 . [DOI] [PubMed] [Google Scholar]
  • 24.Donati S, Maraschini A, Dell’Oro S, Lega I, D’Aloja P. The way to move beyond the numbers: the lesson learnt from the Italian Obstetric Surveillance System. Annali dell’Istituto superiore di sanita. 2019;55(4):363–70. Epub 2019/12/19. doi: 10.4415/ANN_19_04_10 . [DOI] [PubMed] [Google Scholar]
  • 25.Donati S, Maraschini A, Lega I, D’Aloja P, Buoncristiano M, Manno V. Maternal mortality in Italy: Results and perspectives of record-linkage analysis. Acta obstetricia et gynecologica Scandinavica. 2018;97(11):1317–24. Epub 2018/06/30. doi: 10.1111/aogs.13415 . [DOI] [PubMed] [Google Scholar]
  • 26.Morlando M, Sarno L, Napolitano R, Capone A, Tessitore G, Maruotti GM, et al. Placenta accreta: incidence and risk factors in an area with a particularly high rate of cesarean section. Acta obstetricia et gynecologica Scandinavica. 2013;92(4):457–60. Epub 2013/01/26. doi: 10.1111/aogs.12080 . [DOI] [PubMed] [Google Scholar]
  • 27.Stivanello E, Knight M, Dallolio L, Frammartino B, Rizzo N, Fantini MP. Peripartum hysterectomy and cesarean delivery: a population-based study. Acta obstetricia et gynecologica Scandinavica. 2010;89(3):321–7. Epub 2010/01/19. doi: 10.3109/00016340903508627 . [DOI] [PubMed] [Google Scholar]
  • 28.Boldrini R, Di Cesare M, Basili F, Messia I, A G. Certificati di Assistenza al Parto. Analisi Dell’evento Nascita—Anno 2016. Ministero Della Salute Italiana. 2016 [10/2/2021]. www.salute.gov.it/statistiche.
  • 29.Laurita Longo V, Odjidja EN, Beia TK, Neri M, Kielmann K, Gittardi I, et al. "An unnecessary cut?" multilevel health systems analysis of drivers of caesarean sections rates in Italy: a systematic review. BMC pregnancy and childbirth. 2020;20(1):770. Epub 2020/12/12.. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Organisation for Economic Co-operation and Development (OECD). Caesarean sections (indicator) 2019 [10/2/2021]. https://data.oecd.org/healthcare/caesarean-sections.htm
  • 31.Strambi N, Sorbi F, Bartolini GM, Forconi C, Sisti G, Seravalli V, et al. Non-Clinical Variables Influencing Cesarean Section Rate According to Robson Classification. Medicina (Kaunas, Lithuania). 2020;56(4). Epub 2020/04/25. doi: 10.3390/medicina56040180 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Colmorn LB, Petersen KB, Jakobsson M, Lindqvist PG, Klungsoyr K, Källen K, et al. The Nordic Obstetric Surveillance Study: a study of complete uterine rupture, abnormally invasive placenta, peripartum hysterectomy, and severe blood loss at delivery. Acta obstetricia et gynecologica Scandinavica. 2015;94(7):734–44. Epub 2015/04/02. doi: 10.1111/aogs.12639 . [DOI] [PubMed] [Google Scholar]
  • 33.Basili F, Messia I, Montorio V, Tamburini C. Certificato di assistenza al parto—CeDAP National Register Birth [National Birth Register–year 2015] (in Italian). 2015 [cited 2021 2 February]. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2766_allegato.pdf.
  • 34.Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG: an international journal of obstetrics and gynaecology. 2014;121(1):62–70; discussion -1. Epub 2013/08/09. doi: 10.1111/1471-0528.12405 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2019;146(1):20–4. Epub 2019/06/08. doi: 10.1002/ijgo.12761 [DOI] [PubMed] [Google Scholar]
  • 36.Thurn L, Lindqvist PG, Jakobsson M, Colmorn LB, Klungsoyr K, Bjarnadóttir RI, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG: an international journal of obstetrics and gynaecology. 2016;123(8):1348–55. Epub 2015/08/01. doi: 10.1111/1471-0528.13547 . [DOI] [PubMed] [Google Scholar]
  • 37.Khong TY, Werger AC. Myometrial fibers in the placental basal plate can confirm but do not necessarily indicate clinical placenta accreta. American journal of clinical pathology. 2001;116(5):703–8. Epub 2001/11/17. doi: 10.1309/M9BF-6JHH-VF2U-2B8T . [DOI] [PubMed] [Google Scholar]
  • 38.Kayem G, Seco A, Beucher G, Dupont C, Branger B, Crenn Hebert C, et al. Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study. BJOG: an international journal of obstetrics and gynaecology. 2021. Epub 2021/01/05. doi: 10.1111/1471-0528.16647 . [DOI] [PubMed] [Google Scholar]
  • 39.(AgeNaS) ANpiSSR. Programma Nazionale Esiti. Proporzione di parti con taglio cesareo primario. [National Outcome Program. Rate of primary caesarean sections] (in Italian). 2019 [02/10/2021]. https://pne.agenas.it/risultati/tipo1/intr_struasl1_HC.php?ind=37&tipo=2&area=6.
  • 40.Cragin EB. Conservatism in obstetrics. New York Medical Journal 1916;104:1–3. [Google Scholar]
  • 41.Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa-placenta accreta. American journal of obstetrics and gynecology. 1997;177(1):210–4. Epub 1997/07/01. doi: 10.1016/s0002-9378(97)70463-0 . [DOI] [PubMed] [Google Scholar]
  • 42.Comstock CH. Antenatal diagnosis of placenta accreta: a review. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2005;26(1):89–96. Epub 2005/06/23. doi: 10.1002/uog.1926 . [DOI] [PubMed] [Google Scholar]
  • 43.Warshak CR, Ramos GA, Eskander R, Benirschke K, Saenz CC, Kelly TF, et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstetrics and gynecology. 2010;115(1):65–9. Epub 2009/12/23. doi: 10.1097/AOG.0b013e3181c4f12a . [DOI] [PubMed] [Google Scholar]
  • 44.Kingdom JC, Hobson SR, Murji A, Allen L, Windrim RC, Lockhart E, et al. Minimizing surgical blood loss at cesarean hysterectomy for placenta previa with evidence of placenta increta or placenta percreta: the state of play in 2020. American journal of obstetrics and gynecology. 2020;223(3):322–9. Epub 2020/02/03. doi: 10.1016/j.ajog.2020.01.044 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Schwickert A, van Beekhuizen HJ, Bertholdt C, Fox KA, Kayem G, Morel O, et al. Association of peripartum management and high maternal blood loss at cesarean delivery for placenta accreta spectrum (PAS): a multinational database study. Acta obstetricia et gynecologica Scandinavica. 2021. Epub 2021/02/02. doi: 10.1111/aogs.14103 . [DOI] [PubMed] [Google Scholar]
  • 46.Quantitative Blood Loss in Obstetric Hemorrhage: ACOG COMMITTEE OPINION, Number 794. Obstetrics and gynecology. 2019;134(6):e150–e6. Epub 2019/11/26. [DOI] [PubMed] [Google Scholar]
  • 47.Collins SL, Stevenson GN, Al-Khan A, Illsley NP, Impey L, Pappas L, et al. Three-Dimensional Power Doppler Ultrasonography for Diagnosing Abnormally Invasive Placenta and Quantifying the Risk. Obstetrics and gynecology. 2015;126(3):645–53. Epub 2015/07/28. doi: 10.1097/AOG.0000000000000962 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Coutinho CM, Giorgione V, Noel L, Liu B, Chandraharan E, Pryce J, et al. Effectiveness of contingent screening for placenta accreta spectrum disorders based on persistent low-lying placenta and previous uterine surgery. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2021;57(1):91–6. Epub 2020/09/01. doi: 10.1002/uog.23100 . [DOI] [PubMed] [Google Scholar]
  • 49.Melcer Y, Jauniaux E, Maymon S, Tsviban A, Pekar-Zlotin M, Betser M, et al. Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. American journal of obstetrics and gynecology. 2018;218(4):443.e1–.e8. Epub 2018/01/22. doi: 10.1016/j.ajog.2018.01.017 . [DOI] [PubMed] [Google Scholar]
  • 50.Pagani G, Cali G, Acharya G, Trisch IT, Palacios-Jaraquemada J, Familiari A, et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta obstetricia et gynecologica Scandinavica. 2018;97(1):25–37. Epub 2017/10/01. doi: 10.1111/aogs.13238 . [DOI] [PubMed] [Google Scholar]
  • 51.Buca D, Liberati M, Calì G, Forlani F, Caisutti C, Flacco ME, et al. Influence of prenatal diagnosis of abnormally invasive placenta on maternal outcome: systematic review and meta-analysis. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2018;52(3):304–9. Epub 2018/04/17. doi: 10.1002/uog.19070 . [DOI] [PubMed] [Google Scholar]
  • 52.Eller AG, Bennett MA, Sharshiner M, Masheter C, Soisson AP, Dodson M, et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstetrics and gynecology. 2011;117(2 Pt 1):331–7. Epub 2011/02/12. doi: 10.1097/AOG.0b013e3182051db2 . [DOI] [PubMed] [Google Scholar]
  • 53.Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A, et al. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. American journal of obstetrics and gynecology. 2019;221(4):337.e1–.e5. Epub 2019/06/08. doi: 10.1016/j.ajog.2019.05.035 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Shamshirsaz AA, Fox KA, Erfani H, Belfort MA. The Role of Centers of Excellence With Multidisciplinary Teams in the Management of Abnormal Invasive Placenta. Clinical obstetrics and gynecology. 2018;61(4):841–50. Epub 2018/09/11. doi: 10.1097/GRF.0000000000000393 . [DOI] [PubMed] [Google Scholar]
  • 55.Silver RM, Fox KA, Barton JR, Abuhamad AZ, Simhan H, Huls CK, et al. Center of excellence for placenta accreta. American journal of obstetrics and gynecology. 2015;212(5):561–8. Epub 2014/12/03. doi: 10.1016/j.ajog.2014.11.018 . [DOI] [PubMed] [Google Scholar]
  • 56.Kramer MS, Berg C, Abenhaim H, Dahhou M, Rouleau J, Mehrabadi A, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. American journal of obstetrics and gynecology. 2013;209(5):449.e1–7. Epub 2013/07/23. doi: 10.1016/j.ajog.2013.07.007 . [DOI] [PubMed] [Google Scholar]
  • 57.Patterson JA, Roberts CL, Bowen JR, Irving DO, Isbister JP, Morris JM, et al. Blood transfusion during pregnancy, birth, and the postnatal period. Obstetrics and gynecology. 2014;123(1):126–33. Epub 2014/01/28. doi: 10.1097/AOG.0000000000000054 . [DOI] [PubMed] [Google Scholar]
  • 58.Bailit JL, Grobman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW, et al. Morbidly adherent placenta treatments and outcomes. Obstetrics and gynecology. 2015;125(3):683–9. Epub 2015/03/03. doi: 10.1097/AOG.0000000000000680 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.(ISTAT) NIoS. Annuario statistico italiano [Italian Statistics Yearly Report] (in Italian). 2019 [2/10/2021]. https://www.istat.it/it/archivio/236772.
  • 60.Caughey AB, Cahill AG, Guise JM, Rouse DJ. Safe prevention of the primary cesarean delivery. American journal of obstetrics and gynecology. 2014;210(3):179–93. Epub 2014/02/26. doi: 10.1016/j.ajog.2014.01.026 . [DOI] [PubMed] [Google Scholar]
  • 61.Sandall J, Tribe RM, Avery L, Mola G, Visser GH, Homer CS, et al. Short-term and long-term effects of caesarean section on the health of women and children. Lancet (London, England). 2018;392(10155):1349–57. Epub 2018/10/17. doi: 10.1016/S0140-6736(18)31930-5 . [DOI] [PubMed] [Google Scholar]
  • 62.Donati S, Lega I, Maraschini A, Basevi V, Spettoli D, (SNLG) GdlSnpllg. Emorragia post partum: come prevenirla, come curarla. [Postpartum hemorrhage: prevention and management] (in Italian). Linea guida. 2016 [02/13/2021]. http://old.iss.it/binary/moma/cont/LGEPPcorrige.pdf.
  • 63.D’Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2013;42(5):509–17. Epub 2013/08/15. doi: 10.1002/uog.13194 . [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Clive J Petry

27 Apr 2021

PONE-D-21-09866

Characteristics and outcomes of pregnant women with placenta accreta spectrum in Italy: a prospective population-based cohort study.

PLOS ONE

Dear Dr. Ornaghi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This is a well-written manuscript, although it requires some improvement. The authors state that all the relevant data are included with the manuscript, but unfortunately I could not find these at all. As it is a journal requirement this needs to be included in any revision. I would also like to see the Discussion include a (small) section on how the current manuscript enhances the findings published in reference [20]. Both reviewers have suggested other revisions that are required. Reviewer 1's point about the number of removals in the non-suspected group, and reviewer 2's point about how low the ratio of PAS suspected antenatally is, appear to be the most important to revise. However I agree with all their points so encourage dealing with them in any revision. I do not believe that these will be too taxing to complete.

Please submit your revised manuscript by Jun 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Clive J Petry, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients' medical records were accessed; c) the date range (month and year) during which patients whose medical records were selected for this study sought treatment. If the ethics committee waived the need for informed consent, or patients provided informed written consent to have data from their medical records used in research, please include this information.

4. One of the noted authors is a group or consortium [Regional Obstetric Surveillance System Working Group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Congratulation with a well written manuscript.

I have several concerns:

1. high number of missing values: on 61 women the blood loss is not known. This should be reported in the strength & limitation section

2. In table 1 the part on placenta previa: NOT having a placenta previa gives a RR of 227??? Please revise. Is this number correct? Or does it belong to YES having a placenta previa?

3. The number of manual removals in the non-suspected group is much higher than in the group with PAS suspicion: are we looking at another degree of PAS?

4. Alternative ways to handle PAS like focal resection or leaving the placenta in situ (in case of percreta) are not mentioned. Are they not performed? Please comment on this in your manuscript

Reviewer #2: Thanks to the authors for this large-scale study.

Shortly;

In this study, the authors reported that placenta acreta spectrum (PAS) is a life-threatening condition that can lead to severe bleeding, the prevalence increases as the caesaren rates increase, the caesarean rates are high in Italy and the number of quality studies on PAS is low. They were stated that the study was part of a large population-based study on near miss events caused by bleeding, conducted by the Italian obstetric survey system. The aim of the article was to determine the incidence of PAS, to investigate the management of associated factors and perinatal complications, and the results were compared by regions, since there were regions that could not access health services in a balanced way. The authors reported that the study was conducted with about 212 units in a total of six regions from three north and three in the south with an annual birth rate of over 25 000 each. Women with a diagnosis of PAS between the ages of 15-50 over the 22nd gestational week between September 2014 and 2016 were included in the study. This population covers 50% of all births in Italy. As a result of the study, they found the incidence of PAS ‰ 0.84, and reported that although the risk of cases such as placenta previa, low lying placenta, PAS was higher in the southern regions, the possibility of adverse outcomes was lower.

Here is my review and recommendations;

1. Material and methods section; line 196-202

Were the patients in Items 1, 2, 3 also included in the PAS group, or were only the patients specified in Item 4 considered PAS. If so;

Line 196-197 de ‘’severe postpartum hemorrhage, defined as “hemorrhage within 7 days from delivery requiring ≥4 units of whole blood or packed red blood cells ‘’ How was PAS diagnosed in these patients?

Line 197-198 ‘’hemorrhage due to complete or incomplete uterine rupture” How did you rule out non-PAS causes of uterine rupture?

Line 198-199 da (3)“peripartum hysterectomy within 7 days from delivery” How was the diagnosis of PAS made in those without histological examination?

2. Line 236 -238 ‘’Figure 1: Bar graphs show regional and overall prevalence distribution of PAS (white bars), as well as of concomitant placenta previa or low-lying and previous cesarean section among women with PAS’’

Descriptions in the text and explanations below the figure are incompatible

When Figure 1 is examined, it is not fully understood.

White bars: If '' Placenta previa or low-lying and prior CS ''

Gray bars: Cases without PAS risk? Are there vaginal births in this group?

Gray and white bars: All cases of PAS?

Can you please explain and correct in text.

Can you please rearrange Figure 1 in an understandable way?

3. Line 260 ‘’Delivery occurred in facilities in Southern Italy in 65% of the cases’’ is written, but in table 1 this ratio is given as 35.4. Which one is right? Please correct.

4. Line 278 , ‘’PAS was antenatally suspected in 50% of the cases’’

Isn't this ratio too low? Today, evaluation of placenta during fetal anatomical scanning and confirmation at 26th gestational weeks are recommended in various guideline.

Line 419-421 ‘’Knowledge of relevant risk factors for PAS is pivotal to guide a targeted prenatal ultrasound scan and increase the rate of antenatal diagnosis’’

The PAS predicton might be possible in antenatal period with USG and doppler findins such as the loss of the clear zone, presence of placental lacunae, and interruption of the bladder-uterus border according to grey-scale ultrasonography, and increased vascularity in this area based on Doppler USG. According to this, I think 50% is less for the PAS prediction. Isn't antenatal USG performed for every patient in Italy, is it only performed for those with risk factors?

Readers will want to know about routine antenatal care in Italy. Please provide at least one or two paragraphs of information about this.

5. Line 354 Table 3. The title is not clear, does not describe the table

Please change as ‘’Postpartum bleeding and blood transfusion rates according to antenatal suspicion in patients with histologically diagnosed PAS’’

6. There are lots of expression disorders and grammatical errors in the article, so English editing and proofreading should be done.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jun 4;16(6):e0252654. doi: 10.1371/journal.pone.0252654.r002

Author response to Decision Letter 0


9 May 2021

Manuscript requests from the Academic Editor Dr. Clive J Petry, PhD.

We have included a revised statement regarding data availability.

Precisely, data cannot be shared publicly because of ethical standards and legal requirements. Data are available from the Ethics Committee of the Istituto Superiore di Sanità - Italian National Institute of Health (contact via email: segreteria.comitatoetico@iss.it) for researchers who meet the criteria for access to confidential data.

We have now included a brief paragraph in the Discussion section detailing how the findings reported in the current manuscript differentiate from and enhance those published by the same working group regarding peripartum hysterectomy due to obstetric hemorrhage within seven days from delivery in Italy (Maraschini et al., Acta obstetricia et gynecologica Scandinavica. 2020).

Journal requirements

1. We ensure that our manuscript meets PLOS ONE’s style requirements.

2. The reference list has been reviewed and we ensure it is complete and correct. None of the cited papers has been retracted.

3. Women included in the study sought treatment in the participating centers between September 1st, 2014 and August 31st, 2016. Data were fully anonymized before being accessed and analyzed. Since data were analyzed anonymously, need for informed consent was waived by the Ethics Committee of the Istituto Superiore di Sanità - Italian National Institute of Health.

4. All the individual authors of the Regional Obstetric Surveillance System Working Group have now been added, alongside their affiliations, to the Acknowledgments section of our manuscript. The lead author for this group is the senior author of the manuscript, Dr. Serena Donati. We have now specified this information and added her contact email address.

----------------------------------

Dear Referees:

Thank you for the strong positive comments on the first submission of our manuscript. We also appreciate the helpful suggestions as to how we might further improve the paper. Below we respond to each suggestion with details about how we amended the manuscript.

Response to referees.

Response to referee 1.

We appreciate the comment from referee 1 congratulating us on a well written manuscript.

The referee pointed out the high number (61/384, 15.9%) of missing values for the variable ‘blood loss at delivery’ and how this should be highlighted in the Strengths and Limitations section of our manuscript.

Considering the potential for bias due to >10% missingness, we have now included this as a limitation of our research work. However, we also highlighted that the lack of missingness in data regarding first- and second line treatments of PPH has possibly limited the chance of a biased result interpretation.

Referee 1 asked about the role of placenta previa or low-lying as risk factor for PAS since Table 1 shows a relative risk of 227 associated with not having placenta previa or low-lying.

We apologize for the mistake; the relative risk of 227 is associated with having the condition. This has now been corrected in Table 1.

The referee observed that the number of manual removals in the non-suspected group is much higher than in the group with PAS suspicion and this could be the clinical manifestation of another degree of PAS.

We agree with the referee’s observation. Yet, we would like to point out that unsuspected women were also more likely to receive second-line uterotonic drugs, whereas women with antenatal suspicion were more frequently managed with vascular embolization and hysterectomy (Table 2). These data suggest that in the clinical context of a retained placenta, with or without hemorrhage, clinicians might be more prone to manage the condition as subsequent to uterine atony (the most frequent cause) if no antenatal suspicion of PAS is present. Of note, thirty out of 32 unsuspected women with manual removal of the placenta in our cohort delivered vaginally. In addition, when assessing histologically confirmed PAS cases, we did not identify any difference regarding the grade of invasion between women with and without antenatal suspicion, although we are aware that lack of histological report in some of the cases might have affected these findings.

Referee 1 mentioned that alternative ways to hysterectomy for PAS management, including focal resection and leaving the placenta in situ (for cases of placenta percreta), exist but these were not reported in our manuscript.

In our cohort there were four women managed conservatively: three had a partial placenta accreta diagnosed after delivery and only the abnormally adherent cotyledon was left in situ whereas the remaining one had an antenatal diagnosis of complete placenta previa with signs of percretion and no attempt of placenta removal was performed at the time of cesarean section. There were no women in whom the focal resection technique was applied.

We have now included these data in the Results section.

Response to referee 2.

We thank the referee 2 for highlighting that this is a large-scale, population-based study, which can provide useful information to guide national initiatives.

Referee 2 asked whether patients with (1) severe postpartum hemorrhage, defined as “hemorrhage within 7 days from delivery requiring ≥4 units of whole blood or packed red blood cells”; (2) “hemorrhage due to complete or incomplete uterine rupture”; (3) “peripartum hysterectomy within 7 days from delivery”; and (4) PAS, clinically defined as “difficult or incomplete manual removal of the placenta following vaginal delivery and the need of blood transfusion within 48 hours” or “difficult removal of the placenta during cesarean delivery and clinical evidence of an abnormally invasive placenta”, were all included in the present study.

If not, the referee was wondering how PAS was diagnosed in patients with (1), (2), and (3).

PAS was diagnosed clinically, as defined in (4). All women reported as having PAS by the reference clinician in the participating centers were included in the present study, independent of the associated outcomes, such as severe postpartum hemorrhage (1), uterine rupture (2), and peripartum hysterectomy within 7 days from delivery (3), leading to inclusion in the wider ItOSS research project on severe maternal morbidity due to obstetric hemorrhage.

This has been now clarified in the text.

The referee suggested we provide a better description of Figure 1 in the text and we rearrange it in a more understandable way.

We thank the Referee for this comment. We have now included a brief description of Figure 1 in the Results section and amended both the Figure and its caption to improve clarity.

Referee 2 pointed out that Table 1 reports a 35.4% rate of delivery in Southern Italy.

This was a mistake: rate of delivery in Southern Italy was 64.6% whereas rate of delivery in Northern Italy was 35.4%. This has now been corrected in Table 1.

The referee was wondering whether the reported rate of antenatal suspicion (50%) might be too low, considering the current ultrasound techniques that allow an in-depth investigation of the placenta during gestation.

We agree with the referee that a detailed ultrasound scan, particularly in high-risk women, is pivotal in antenatally suspecting PAS through identification of suggestive signs, such as the loss of the clear zone, the presence of placental lacunae, and the interruption of the bladder-uterus border at grey-scale investigation, and the increased vascularity in the area at Doppler assessment. We also recognize that these ultrasound signs are included in several guidelines on the topic.

However, we kindly disagree with the referee suggesting that a 50% rate of antenatal diagnosis is too low. This rate is similar to that reported by the UKOSS study (66/134, 49.3%) (Fitzpatrick et al., 2014) and the French study (106/242, 43.8%), (Kayem et al., 2021) and substantially higher than that of the NOSS study (60/205, 29.3%) (Thurn et al., 2016), which all had a time period for women’s inclusion in the project similar to ours.

It is likely that currently ongoing research works on PAS, including women in more recent years, might show higher rates of antenatal suspicion, given the increased prevalence and thus awareness of this condition and the institution of dedicated PAS diagnostic services for high-risk women in tertiary care centers, as recently reported by Bhide and colleagues. (Coutinho et al., 2021).

Referee 2 suggested to modify the title of Table 3 to improve clarity.

We appreciate the referee’s suggestion and we have now changed the title as per the referee’s indications.

The referee pointed out the presence of expression disorders and grammatical errors in the manuscript.

The manuscript has now been proofread by a native English speaker, thus hopefully improving its readability.

References (almost all of these citations are also included in the manuscript)

Coutinho CM, Giorgione V, Noel L, Liu B, Chandraharan E, Pryce J, Frick AP, Thilaganathan B, Bhide A (2021) Effectiveness of contingent screening for placenta accreta spectrum disorders based on persistent low-lying placenta and previous uterine surgery. Ultrasound Obstet Gynecol 57:91-96.

Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M (2014) The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. Bjog 121:62-70; discussion 70-61.

Kayem G et al. (2021) Clinical profiles of placenta accreta spectrum: the PACCRETA population-based study. Bjog.

Thurn L, Lindqvist PG, Jakobsson M, Colmorn LB, Klungsoyr K, Bjarnadóttir RI, Tapper AM, Børdahl PE, Gottvall K, Petersen KB, Krebs L, Gissler M, Langhoff-Roos J, Källen K (2016) Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. Bjog 123:1348-1355.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Clive J Petry

20 May 2021

Characteristics and outcomes of pregnant women with placenta accreta spectrum in Italy: a prospective population-based cohort study.

PONE-D-21-09866R1

Dear Dr. Ornaghi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Clive J Petry, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Clive J Petry

25 May 2021

PONE-D-21-09866R1

Characteristics and outcomes of pregnant women with placenta accreta spectrum in Italy: a prospective population-based cohort study.

Dear Dr. Ornaghi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Clive J Petry

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly because of ethical standards and legal requirements. Data are available from the Ethics Committee of the Istituto Superiore di Sanità - Italian National Institute of Health (contact via email: segreteria.comitatoetico@iss.it) for researchers who meet the criteria for access to confidential data.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES